To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to Medical Devices; Laboratory Developed Tests, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill blocks the FDA from using any federal money to enforce a May 2024 rule that would regulate laboratory developed tests (LDTs) as medical devices. LDTs are diagnostic tests created and used within a single laboratory, such as genetic tests or COVID screening tests developed by hospitals. The FDA rule would require these tests to go through the same approval process as commercial medical devices.
Who Benefits and How
Clinical laboratories and hospital diagnostic labs benefit directly by avoiding costly FDA premarket review requirements that could run into hundreds of thousands of dollars per test. Diagnostic testing companies, particularly those offering specialized genetic testing services, would also benefit by continuing to operate without federal device approval. The bill preserves their ability to develop and offer new tests quickly without FDA oversight.
Who Bears the Burden and How
Patients may face increased risk from laboratory tests that have not undergone independent FDA safety and effectiveness review. The FDA loses authority to oversee an estimated 12,000+ laboratory developed tests currently on the market. Public health advocates argue this could leave dangerous or inaccurate tests unregulated.
Key Provisions
- Prohibits any federal funds from being used to implement, administer, or enforce the FDA's May 2024 final rule on Laboratory Developed Tests
- Applies to the specific rule published in the Federal Register on May 6, 2024 (89 Fed. Reg. 37286)
- Also blocks enforcement of any "substantially similar" future rules, preventing the FDA from issuing a revised version
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
This bill prohibits the use of federal funds to implement, administer, or enforce a specific FDA final rule relating to medical devices and laboratory developed tests.
Key Policy Areas
Healthcare
Primary Purpose
This bill prohibits the use of federal funds to implement, administer, or enforce a specific FDA final rule relating to medical devices and laboratory developed tests.
Policy Domains
Sponsors
Brad Finstad
R-MN | Primary Sponsor
Legislative Progress
IntroducedMr. Finstad (for himself and Mr. Crenshaw) introduced the following …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology